Cargando…
Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to ch...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791/ https://www.ncbi.nlm.nih.gov/pubmed/30209885 http://dx.doi.org/10.1111/1759-7714.12861 |
_version_ | 1783366970569129984 |
---|---|
author | Nakamura, Yuki Kobayashi, Tetsu Nishii, Yoichi Suzuki, Yuta Saiki, Haruko Ito, Kentaro Watanabe, Fumiaki Nishihama, Kota Yasuma, Taro D'Alessandro‐Gabazza, Corina N. Katsuta, Koji Fujimoto, Hajime Gabazza, Esteban C Taguchi, Osamu Hataji, Osamu |
author_facet | Nakamura, Yuki Kobayashi, Tetsu Nishii, Yoichi Suzuki, Yuta Saiki, Haruko Ito, Kentaro Watanabe, Fumiaki Nishihama, Kota Yasuma, Taro D'Alessandro‐Gabazza, Corina N. Katsuta, Koji Fujimoto, Hajime Gabazza, Esteban C Taguchi, Osamu Hataji, Osamu |
author_sort | Nakamura, Yuki |
collection | PubMed |
description | BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD‐L1 in non‐small cell lung cancer (NSCLC). METHODS: This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28‐8 antibodies. RESULTS: There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28‐8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28‐8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28‐8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis. CONCLUSION: In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD‐L1 in NSCLC. |
format | Online Article Text |
id | pubmed-6209791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-62097912018-11-16 Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer Nakamura, Yuki Kobayashi, Tetsu Nishii, Yoichi Suzuki, Yuta Saiki, Haruko Ito, Kentaro Watanabe, Fumiaki Nishihama, Kota Yasuma, Taro D'Alessandro‐Gabazza, Corina N. Katsuta, Koji Fujimoto, Hajime Gabazza, Esteban C Taguchi, Osamu Hataji, Osamu Thorac Cancer Original Articles BACKGROUND: Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD‐L1 and PD‐1 receptor have remarkably improved the therapeutic response and survival of cancer patients. The tumor expression level of PD‐L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD‐L1 in non‐small cell lung cancer (NSCLC). METHODS: This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28‐8 antibodies. RESULTS: There was a significant correlation between the immunoreactivity rate of tumor tissues obtained using 22C3 and 28‐8 clones. No statistical difference in immunoreactivity between archival and recent samples stained either with 22C3 or 28‐8 antibodies was observed. The immunoreactivity rate achieved with 22C3 or 28‐8 antibodies significantly correlated with tumor histological type and size, but not with specimen storage time, age, gender, smoking history, clinical stage, or lymph node metastasis. CONCLUSION: In brief, the results of this study show that the time interval between tissue sampling/paraffinization and immunohistochemical analysis has no influence on the immunoreactivity rate of PD‐L1 in NSCLC. John Wiley & Sons Australia, Ltd 2018-09-12 2018-11 /pmc/articles/PMC6209791/ /pubmed/30209885 http://dx.doi.org/10.1111/1759-7714.12861 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Nakamura, Yuki Kobayashi, Tetsu Nishii, Yoichi Suzuki, Yuta Saiki, Haruko Ito, Kentaro Watanabe, Fumiaki Nishihama, Kota Yasuma, Taro D'Alessandro‐Gabazza, Corina N. Katsuta, Koji Fujimoto, Hajime Gabazza, Esteban C Taguchi, Osamu Hataji, Osamu Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer |
title | Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer |
title_full | Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer |
title_fullStr | Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer |
title_full_unstemmed | Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer |
title_short | Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer |
title_sort | comparable immunoreactivity rates of pd‐l1 in archival and recent specimens from non‐small cell lung cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209791/ https://www.ncbi.nlm.nih.gov/pubmed/30209885 http://dx.doi.org/10.1111/1759-7714.12861 |
work_keys_str_mv | AT nakamurayuki comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT kobayashitetsu comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT nishiiyoichi comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT suzukiyuta comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT saikiharuko comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT itokentaro comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT watanabefumiaki comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT nishihamakota comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT yasumataro comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT dalessandrogabazzacorinan comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT katsutakoji comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT fujimotohajime comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT gabazzaestebanc comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT taguchiosamu comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer AT hatajiosamu comparableimmunoreactivityratesofpdl1inarchivalandrecentspecimensfromnonsmallcelllungcancer |